Neurocytotron on Cerebral Palsy

Cerebral Palsy Clinical Trial

Official title: A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Neurocytotron in Patients With Cerebral Palsy

Status Completed

Clinical Trial Summary

This is a randomized, double-blinded, two-arm, placebo-controlled clinical study. The enrollment will be randomized 1:1 to Neurocytotron treatment or mock treatment (placebo).

Upon the completion of the study period, the placebo group will receive treatment, if the study results show benefits to patients.

Clinical Trial Description

The study proposes to investigate the use of non-thermal and non-radioactive radiofrequency pulses in the brain for improving the symptoms of cerebral palsy. The proposed treatment will deliver radiofrequency pulses to the brain of patients in a non-invasive manner. The duration of the treatment will be 1 hour per day, for 28 days. After treatment, participants will be monitored for two months to detect potential adverse events and any signs of symptoms improvement. The study will be closed once 48 subjects complete the study. At the end of the study, the placebo group will have the opportunity to receive treatment with the Neurocytotron, based on the benefits shown by study results. ;

Related Conditions & MeSH terms

• Cerebral Palsy

• NCT number: NCT03743623
• Study type: Interventional
• Source: Neurocytonix, Inc.
• Status: Completed
• Phase: N/A
• Start date: March 22, 2019
• Completion date: June 11, 2021